美托洛尔联合稳心颗粒治疗冠心病心律失常临床观察

目的：探讨美托洛尔联合稳心颗粒治疗冠心病心律失常的临床疗效及安全性。方法：选取冠心病心律失常患者182例,随机分为对照组和观察组,各91例,对照组给予美托洛尔治疗,观察组给予美托洛尔联合稳心颗粒治疗,比较两组患者治疗后疗效及不良反应发生率。结果：对照组总有效率73.62%,观察组96.70%,组间差异比较有显著统计学意义（P〈0.01）;对照组不良反应发生率13.19%,观察组6.95%,组间差异比较无统计学意义（P〉0.05）。结论：美托洛尔联合稳心颗粒治疗冠心病心律失常临床疗效显著,且安全性好,应广泛推广应用。

Clinical observation on treating coronary heart disease plus arrhythmia with metoprolol plus the Wenxin granule

Objective： To investigate clinical effects and security of metoprolol plus the Wenxin granule on coronary heart disease and arrhythmia. Methods： 182 cases with coronary heart disease and arrhythmia were randomly divided into two groups. The control group （91 cases） was treated with metoprolol, and the treatment group （91 cases） was treated with metoprolol and the Wenxin granule. Clinical efficacy and adverse reactions in two groups were compared. Results： After treatment, the total efficiency in treatment group （96.70%） was significantly higher than that in the control group （73.62%） （P〈0.01）. The incidence of adverse reactions in treatment group （6.95%） was lower than that （13.19%） in the control group （P〉0.05）. Conclusion： Metoprolol and the Wenxin granule on coronary heart disease plus arrhythmia showed significant clinical efficacy and safety.